



Proskauer» Global Capital Markets  
IPO Study 2019

# Principal Contacts

## New York



**Daniel L. Forman**  
Senior Counsel  
Global Capital Markets  
+1.212.969.3096  
dforman@proskauer.com



**Frank J. Lopez**  
Partner  
Co-head, Global Capital Markets  
+1.212.969.3492  
flopez@proskauer.com

## Boston



**Lily Desmond**  
Senior Counsel  
Global Capital Markets  
+1.617.526.9641  
ldesmond@proskauer.com

## Washington, D.C.



**Karen Garnett**  
Partner  
Global Capital Markets  
+1.202.416.6850  
kgarnett@proskauer.com



**William J. Tuttle**  
Partner  
Global Capital Markets  
+1.202.416.6860  
wtuttle@proskauer.com

## London



**Peter Castellon**  
Partner  
Global Capital Markets  
+44.20.7280.2091  
pcastellon@proskauer.com



**Maximilian Kirchner**  
Partner  
Global Capital Markets  
+44.20.7280.2074  
mkirchner@proskauer.com

## Chicago



**Michael J. Choate**  
Partner  
Global Capital Markets  
+1.312.962.3567  
mchoate@proskauer.com

## Sao Paulo



**Antonio Piccirillo**  
Partner  
Head of Sao Paulo Office  
Global Capital Markets  
+1.212.969.3905  
apiccirillo@proskauer.com

We hope you enjoy Proskauer's 2019 IPO Study. Please feel free to contact any of the Global Capital Markets attorneys listed here with any questions on this report.

Contents

2018 Market Overview 1

Trend Analysis 43

Health Care 59

Technology, Media & Telecommunications 75

Consumer/Retail 91

Financial Services 107

Industrials 121

Appendix A - Sponsor-Backed Issuers

Appendix B - Foreign Private Issuers

These materials are proprietary to Proskauer Rose LLP and may not be reproduced, transmitted or otherwise exploited in any media, in whole or in part, without the prior written authorization of Proskauer Rose LLP. Requests for permission may be addressed to: Frank Lopez, Co-head of Global Capital Markets, Proskauer Rose LLP.

This publication includes the presentation of statistical information for illustrative purposes only and should not be relied on for any inference of correlative or causal relationships. Although we believe our study is an accurate representation of the IPO market that meets our study's criteria, there may be slight deviations from the actual market.

This publication is a service to our clients and friends of the firm. This publication is not intended to be comprehensive or to provide financial, investment, legal, tax or other professional advice or services. This publication is not a substitute for such professional advice or services, and it should not be acted on or relied upon or used as a basis for any investment or other decision or action that may affect you or your business. Before making any such decision you should consult a suitably qualified professional adviser. While reasonable effort has been made to ensure the accuracy of the information contained in this publication, this cannot be guaranteed and neither Proskauer Rose LLP nor any other related entity shall have any liability to any person or entity that relies on the information contained in this publication, including incidental or consequential damages arising from errors or omissions. Any such reliance is solely at the user's risk.



# Methodology

## Population

Our proprietary database now includes 556 IPOs that priced from 2013 to 2018.

The criteria for our study include:

- Listing on a U.S. national securities exchange; and
- Minimum initial base deal of \$50mm in the first preliminary prospectus that included a price range filed with the SEC.

The total population that met our criteria in 2018 was 152 IPOs.

This study covers 94 IPOs (approximately 62% of the IPOs that met our criteria) that priced in 2018: 72 domestic issuers and 22 foreign private issuers (FPIs). Our population is reflective of the total population based on industry, size and geographic region.

Our trend analysis section covers 456 IPOs: 94 in 2018, 86 in 2017, 67 in 2016, 90 in 2015 and 119 in 2014.

Our study excludes blank check companies (BCCs), special purpose acquisition companies (SPACs), trusts, real estate investment trusts (REITs), business development companies (BDCs) and closed-end investment companies.

There are two appendices in our study for Sponsor-backed IPOs and FPIs that priced in 2018.

## Sources and Analysis

Data compiled from publicly available: (i) registration statements on Form S-1, Form S-11 and Form F-1 and final prospectuses, (ii) SEC comment letters and (iii) as-filed underwriting agreements.

Market, sector, pricing, over-allotment, sponsor-backed and performance data are sourced from Dealogic.

Financial information (unless otherwise indicated) is based on the issuer's most recent audited fiscal year as disclosed in the final prospectus.

The term "average offer" in the "Aftermarket Performance" charts means the average percentage change from the IPO price to the closing price on one day, 30 days, 90 days or 180 days (excludes deals priced after August 1, 2018) after the initial trade date and includes market data available as of January 31, 2018 (our cut-off date).

Analysis of first round SEC comment letters and time to pricing excludes three issuers that either received SEC comments on a prior IPO registration statement or were previously reporting issuers.


Analysis of corporate governance items excludes Master Limited Partnerships (MLPs) and FPIs, given their unique corporate governance structures and available exemptions under stock exchange rules.

Non-Generally Accepted Accounting Principles (Non-GAAP) financial measures include Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA, adjusted net income and free cash-flow.

# 2018 Market Overview


# Sector Analysis

Health Care IPOs made up the largest percentage of deals in the overall IPO market.



# U.S. Geographic Analysis

California and Massachusetts were the top U.S. states for IPO issuer headquarters.




## State of Headquarters

- California - 33%
- Massachusetts - 21%
- Texas - 7%
- Georgia - 4%
- New York - 3%
- Other - 32%

**83%**

of California-based issuers were headquartered in the Bay Area.




## State of Incorporation

- Delaware - 88%
- Nevada - 3%
- Washington - 3%
- Other - 6%

Delaware was the top U.S. state for IPO issuer states of incorporation.

# Global Geographic Analysis


2018 saw a significant increase in IPOs from China as a percentage of the overall market, up to 16% from 8% in 2017. This was the highest percentage of Chinese issuers that we have seen in the last five years.






# Deal Size & Market Capitalization at Pricing

Almost half of IPOs had a deal size of between \$100mm and \$249mm.



Deal Size\*



Market Cap at Pricing


\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Exercise of Over-Allotment Option

The over-allotment option was exercised in approximately


**77%**

of IPOs.




Exercise of Over-Allotment Option


- Option exercised in full or part - 77%
- Option not exercised - 23%



Exercise of Over-Allotment Option by Sector



**Exercise of Over-Allotment Option by Deal Size\***







**Exercise of Over-Allotment Option by Market Cap at Pricing**

\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Pricing vs. Range

Approximately  
**61%**  
of IPOs priced  
in range.






\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Confidential Submission

The SEC permits issuers to utilize a confidential submission process in connection with its review of IPO registration statements. This confidential review process has been expanded by the JOBS Act, the FAST Act and SEC guidance.

.....  
The only issuer in our study that did not confidentially submit was AXA Equitable Holdings, Inc.  
.....



## Confidential Submission

- Issuers confidentially submitting - 99%
- Issuers not confidentially submitting - 1%




# Time to IPO

The average number of days from an initial submission/filing of an IPO registration statement to pricing was


# 139

days.


## Average Number of Days from First Submission/Filing to Pricing\*



## By Sector



## By Deal Size\*\*



## By Market Cap at Pricing


\*Excludes three prior SEC-reviewed issuers.

\*\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Emerging Growth Companies (EGCs)

EGCs are a class of issuers established under the JOBS Act that are afforded greater flexibility in pursuing their IPOs. Generally, EGCs are issuers with less than \$1.07 billion of annual gross revenue during their most recently completed fiscal year.


Approximately  
**86%**  
of IPO issuers  
were EGCs.



EGCs by Sector


# Financial Information & EGCs

Most EGCs took advantage of the scaled financial disclosure requirements afforded to them under the JOBS Act.




**Years of Audited Financial Statements\***

- 2 Years - 81%
- 3 Years - 19%



**Years of Selected Financial Statements\***

- 2 Years - 71%
- 3 Years - 23%
- 5 Years - 6%



**Years of Audited Financial Statements in Initial Draft Registration Statement\*\***

- 1 Year - 15%
- 2 Years - 77%
- 3 Years - 8%

\*Non-EGCs are excluded as well as two EGCs that provided financial statements since inception, which period was shorter than two years, and one EGC that only showed seven months of unaudited financial statements as the issuer was previously in bankruptcy. The JOBS Act provides scaled financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.


\*\*Pursuant to the FAST Act, issuers are permitted to omit audited and interim financial statements in initial submissions for prior periods that would not otherwise be required in the prospectus at pricing.

# EBITDA and/or Adjusted EBITDA

In addition to financial measures calculated in accordance with generally accepted accounting principles, many issuers disclose non-GAAP measures, including EBITDA and Adjusted EBITDA.


**37%**

of issuers disclosed EBITDA and/or Adjusted EBITDA.



**Disclosure of EBITDA and/or Adjusted EBITDA**

- EBITDA and/or Adjusted EBITDA disclosed - 37%
- Neither EBITDA nor Adjusted EBITDA disclosed - 63%



**Disclosure of EBITDA and/or Adjusted EBITDA by Sector**


# Operating Metrics

Operating metrics are non-financial performance measures and vary by sector.

Operating metrics include measures such as backlog, paying users and customer retention rates.


Operating metrics were disclosed in the summary financials in

**32%**  
of IPOs.



Disclosure of Operating Metrics

- Operating metrics included - 32%
- Operating metrics not included - 68%



Disclosure of Operating Metrics by Sector

Based on review of summary financial information.

# Flash Results

“Flash results” refer to estimated, unaudited financial results for a recently completed fiscal period that are disclosed before complete financial statements are available. They are typically presented as ranges and often cover only select financial line items or operating metrics. They are not required under accounting rules but are often presented for disclosure reasons, particularly the closer the offering date is to the date the financial statements become stale.



46 IPOs priced within 45 days after the end of the fourth fiscal quarter of 2017 or the first, second or third fiscal quarter of 2018. 23 of these 46 issuers (50%) included flash results.

**26%**

of issuers included flash results.

**50%**

of issuers pricing within 45 days of a quarter end included flash results.



For IPOs, audited annual financial statements for the most recently completed fiscal year need to be included no later than 45 days after the end of the fiscal year and unaudited interim financial statements for the most recently completed fiscal quarter (other than the fourth quarter) need to be included no later than 134 days after the date of the most recent balance sheet included in the registration statement. For example, first quarter unaudited financial statements go stale at the end of the 134th day after the first quarter and an issuer would need to file second quarter unaudited financial statements with its registration statement on the 135th day.




# Pro Forma Financial Statements

The SEC rules require issuers to include standalone pro forma financial statements in connection with certain material acquisitions, dispositions or other significant transactions where disclosure would be material to investors.


**13%**

of issuers included pro forma financial statements.



**Inclusion of Pro Forma Financial Statements**


- Pro forma financial statements included - 13%
- Pro forma financial statements not included - 87%



**Inclusion of Pro Forma Financial Statements by Sector**


# Accounting/Internal Controls

Almost half of issuers that went public disclosed a material weakness in internal control over financial reporting.




## Issuers with a Going Concern Qualification

- Issuers with a going concern - 22%
- Issuers without a going concern - 78%




## Issuers with a Material Weakness

- Issuers with a material weakness - 46%
- Issuers without a material weakness - 54%




## Issuers with Restated Financial Statements

- Issuers with restated financials - 7%
- Issuers without restated financials - 93%




**Pricing vs. Range - Going Concern**

- Above range
- In range
- Below range



**Pricing vs. Range - Material Weakness**

- Above range
- In range
- Below range



**Pricing vs. Range - Restated Financial Statements**


- Above range
- In range
- Below range

# SEC Comments: Total First Round Comments

Average number of total first round comments decreased from 23 in 2017 to


# 20

in 2018.



Average Number of First Round SEC Comments by Sector

- Low
- Average
- Median
- High



Average Number of SEC Comments by Round

- First round comments
- Second round comments
- Third round comments


Excludes three prior SEC-reviewed issuers.

# SEC Comments: Financial & Accounting Comments

Financial and accounting comments include those on the summary financial and selected financial data, capitalization, management's discussion & analysis (MD&A), historical financial statements (F-pages) and pro forma financial statements.


The average number of financial and accounting comments decreased from 10 in 2017 to

**seven**  
in 2018.




Excludes three prior SEC-reviewed issuers.

# SEC Comments: A Closer Examination




## Cheap Stock Comments by Sector\*

Overall: 53%



## Revenue Recognition Comments by Sector

Overall: 37%




## Segment Reporting Comments by Sector

Overall: 16%

Excludes three prior SEC-reviewed issuers.


\*Cheap stock comments relate to the difference in valuation represented by (1) pre-IPO equity grants, typically in the form of options to purchase stock issued to officers or directors, and (2) the expected IPO price.





**Non-GAAP Financial Measures Comments by Sector**

Overall: 25%




**Executive Compensation/Employment Arrangements Comments by Sector**

Overall: 27%

Excludes three prior SEC-reviewed issuers.


# Capital Structure

.....  
Issuers with multiple classes of common stock continued to be found predominantly in the TMT sector.  
.....



**Issuers with Multiple Classes of Common Stock**


- Issuers with multiple classes of common stock - 15%
- Issuers with a single class of common stock - 85%



**Issuers with Multiple Classes of Common Stock by Sector**


Overall: 15%

Excludes FPIs (subject to home jurisdiction governance rules).



**Pricing vs. Range - Capital Structure**

- Above range
- In range
- Below range



**Aftermarket Performance - Capital Structure**

- Issuers with multiple classes of common stock
- Issuers with a single class of common stock
- All IPOs


Excludes FPIs (subject to home jurisdiction governance rules).

# Board Structure: Director Independence




## Size of Board at Pricing

- Average number of directors at pricing - 8



## Size of Board at Pricing

- Average number of independent directors at pricing - 5




## Board Independence at Pricing

- Majority independent directors at pricing - 76%
- Less than a majority of independent directors at pricing - 24%

Excludes FPIs (subject to home jurisdiction governance rules).


# Board Structure: Classified Board

Approximately  
**92%**  
of issuers went public with a classified board.




Issuers with a Classified Board at Pricing

- Issuers with a classified board - 92%
- Issuers without a classified board - 8%



Pricing vs. Range -  
Classified Board

- Above range
- In range
- Below range




Aftermarket  
Performance -  
Classified Board

- Issuers with a classified board
- Issuers without a classified board
- All IPOs


Excludes FPIs (subject to home jurisdiction governance rules).

# Board Structure: Separation of Chair & CEO Roles




**Separation of Chair and CEO Roles**

- Separation of Chair and CEO roles - 72%
- Chair and CEO roles combined - 28%



**Pricing vs. Range - Separation of Chair and CEO Roles**

- Above range
- In range
- Below range





**Aftermarket Performance - Separation of Chair and CEO Roles**

- Separation of Chair and CEO roles
- Chair and CEO roles combined
- All IPOs

Excludes three issuers that did not have a Chair at the time of IPO and FPIs (subject to home jurisdiction governance rules).




# Anti-Takeover Measures and Exclusive Forum Provisions




Excludes FPIs (subject to home jurisdiction governance rules).

Certain anti-takeover measures are implemented to spring into effect upon a trigger event, such as a significant stockholder's ownership position falling below a certain threshold.



### Restrictions on Stockholder Ability to Call Special Meeting

- Yes - 76%
- Subject to trigger - 10%
- No - 14%



### Exclusive Forum Provisions\*

- Yes - 87%
- No - 13%

Excludes FPIs (subject to home jurisdiction governance rules).

Certain anti-takeover measures were implemented to spring into effect upon a trigger event, such as a significant stockholder's ownership position falling below a certain threshold.

\*Exclusive forum provisions limit the courts in which certain types of stockholder litigation can be brought.

# Equity Incentive Plan

Most issuers establish a new equity incentive plan upon going public and reserve a specified number of shares to issue as compensation to officers, directors and employees.


The average percentage of shares reserved under equity incentive plans was

**8.5%**

Approximately

**40%**

of issuers also established employee stock purchase programs.




Average Percentage of Shares Reserved Under Equity Incentive Plans by Sector

# Secondary Component

IPOs with a secondary component provide for sales of shares by existing stockholders of the company.


**18%**

of IPOs had one or more selling stockholders.




IPOs with a Secondary Component

- IPOs with a secondary component - 18%
- IPOs without a secondary component - 82%



Pricing vs. Range - Secondary Component

- Above range
- In range
- Below range



Aftermarket Performance - Secondary Component

- IPOs with a secondary component
- IPOs without a secondary component
- All IPOs

Deals with one or more selling stockholders selling in the over-allotment option are not included.

# Management Sales

Directors and/or officers participated as selling stockholders in the base offering of


## 47%

of IPOs with a secondary component.




### Management Selling in Secondary Component of IPO

- Secondary IPOs with management selling - 47%
- Secondary IPOs without management selling - 53%



### Pricing vs. Range - Management Sales

- Above range
- In range
- Below range




### Aftermarket Performance - Management Sales

- Secondary IPOs with management selling
- Secondary IPOs without management selling
- All IPOs


# Insiders Purchasing

Almost half of issuers disclosed directors, officers or existing stockholders purchasing in their IPO.




IPOs with Insiders Purchasing

- IPOs with insiders purchasing - 47%
- IPOs without insiders purchasing - 53%




Insiders Purchasing in IPO by Sector

Does not include purchases through a Directed Share Program (DSP).



### Insiders Purchasing in IPO by Deal Size\*

Overall: 47%



### Insiders Purchasing in IPO by Market Cap at Pricing


Overall: 47%

Excludes purchases through a DSP.

\*Deal size consists of priced amount in base offering and excludes an exercise of the over-allotment option.


# Insiders Purchasing

IPOs with insiders purchasing were more likely to price in or above range.



Pricing vs. Range - Insiders Purchasing in IPO

- Above range
- In range
- Below range



Aftermarket Performance - Insiders Purchasing in IPO

- IPOs with insiders purchasing
- IPOs without insiders purchasing
- All IPOs


Does not include purchases through a DSP.



# Pre-IPO Private Placements


**47%**

of issuers issued equity securities within 12 months prior to submitting/filing IPO registration statements.



**Issuers Privately Placing Equity Securities within 12 months prior to Submitting/Filing IPO Registration Statement**

- Yes - 47%
- No - 53%



**Pre-IPO Private Placements by Sector**

Based on review of information disclosed in Part II, Item 15 of Form S-1 registration statements and Part II, Item 7 of Form F-1 registration statements.

# Directed Share Programs (DSPs)

Directed Share Programs (DSPs) allow insiders, employees and other individuals that have relationships with the issuer to purchase stock in the IPO. At the request of the issuer, the underwriters reserve a certain amount of the shares in the IPO for purchase by DSP participants.


**41%**

of issuers established DSPs.

The average size for DSPs was


**5%**

of the base deal size.



Directed Share Programs (DSPs)

- Issuers that offered DSPs - 41%
- Issuers that did not offer DSPs - 59%



DSPs by Sector

# Lock-ups

Typically, lock-up release rights are negotiated between the bookrunners and the issuer. The parties that control release rights may, prior to the expiration of the lock-up period, permit the issuer and/or certain stockholders to sell shares in an organized follow-on offering or freely into the open market.


Lock-up release rights were held solely by the lead left bookrunner in

**9%**

of IPOs.


**71%**

of issuers had a lock-up carve-out for issuances in connection with acquisitions or joint ventures.



**Lock-up Release**

- Lead left bookrunner only - 9%
- Multiple bookrunners - 91%




**Carve-outs for Issuances in Connection with Acquisitions or Joint Ventures\***

- 5% carve-out - 49%
- 7% carve-out - 5%
- 10% carve-out - 13%
- Uncapped carve-out - 4%
- Carve-out not included - 29%

\*Carve-out from issuer lock-up for equity issuances in connection with acquisitions, joint-ventures and strategic transactions.

# IPO Fees & Expenses

Underwriting fees ranged from \$2.8mm to \$67.5mm. The median value for the underwriting fee as a percentage of the base deal size was 7%.



Average Fees and Expenses as % of Base Deal

- Average
- Median

| Fee Category        | Low         | Average      | Median       | High         |
|---------------------|-------------|--------------|--------------|--------------|
| Underwriting Fees*  | \$2,800,000 | \$15,255,898 | \$10,132,500 | \$67,500,000 |
| Total IPO Expenses  | \$1,055,000 | \$5,624,453  | \$4,052,528  | \$88,100,000 |
| Legal Expenses      | \$375,000   | \$2,241,141  | \$1,850,000  | \$15,000,000 |
| Accounting Expenses | \$80,000    | \$1,855,186  | \$1,027,400  | \$50,000,000 |
| Printing Expenses   | \$35,000    | \$377,912    | \$325,000    | \$2,000,000  |

IPO Fees and Expenses



\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.








# Trend Analysis

# Sector Analysis






# Deal Size and Market Capitalization at Pricing




\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Confidential Submission




**EGCs Electing to Confidentially Submit**



**Issuers Electing to Confidentially Submit\***


\*Includes both EGCs and Non-EGCs.

# Time to IPO




Excludes prior SEC-reviewed issuers and an additional two issuers in 2014, one issuer in 2015, two issuers in 2016 and nine issuers in 2017 with time from first submission/filing to pricing greater than 18 months.

# Financial Information & EGCs




**EGCs that Included  
Two Years of Audited  
Financial Statements**




**EGCs that Included  
Two Years of Selected  
Financial Statements**

Excludes two EGCs in 2015, three EGCs in 2016, one EGC in 2017 and two EGCs in 2018 that provided financial statements since inception, which period, in each case, was less than two years, and one that only showed seven months of unaudited financial statements as the issuer was previously in bankruptcy.

# EBITDA, Adjusted EBITDA and Operating Metrics





Disclosure of EBITDA and/or Adjusted EBITDA




Disclosure of Operating Metrics\*

\*Based on review of summary financial information.


# Pre-Revenue Issuers and Issuers with a Net Loss




# Accounting/Internal Controls



Issuers with a Going Concern Qualification




Issuers with a Material Weakness




Issuers with Restated Financials

# SEC Comments

There continues to be a year-over-year decrease in the average number of first round comments received by issuers from the SEC.



Average Number of First Round SEC Comments




Average Number of Financial and Accounting Comments\*

Excludes prior SEC-reviewed issuers.


\*Financial and accounting-related comments include those on the summary financial and selected financial data, capitalization, management's discussion & analysis (MD&A), historical financial statements (F-pages) and pro forma financial statements.



# SEC Comments




Percentage of IPOs with Revenue Recognition Comments




Percentage of IPOs with Non-GAAP Financial Comments

Excludes prior SEC-reviewed issuers.

# Secondary Component and Insiders Purchasing




Percentage of IPOs with a Secondary Component



Percentage of IPOs with Insiders Purchasing\*


\*Does not include purchases through a DSP

# Directed Share Programs (DSPs)




# Sponsor-backed IPOs

There continues to be a decrease in the percentage of IPOs that were backed by sponsors.




Percentage of IPOs that are Sponsor-backed

# IPO Fees and Expenses



Average IPO Fees and Expenses\*



IPO Fees and Expenses as a Percentage of Base Deal Size

\*Excludes underwriting fees.



# Health Care

# Health Care Market Overview

Health Care IPOs

**42%**


of overall market




**97%**

of Health Care issuers in our study were biotech or biopharmaceutical companies.

## Sector Overview




- Health Care IPOs - 42%
- All other IPOs - 58%




Region of Headquarters




Moderna, Inc., which priced in December 2018, was the largest biotech firm to go public with a deal size of approximately \$604mm.



Deal Size\*



Over-Allotment Option Exercised





Market Cap at Pricing



- Small-cap (<\$350mm) - 26%
- Mid-cap (\$350mm-\$1bn) - 59%
- Large-cap (\$1bn+) - 15%

\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option

# Market Performance




# Emerging Growth Companies (EGCs)



## Years of Audited Financial Statements\*

- 2 Years - 97%
- 3 Years - 3%







## Years of Selected Financial Statements\*



- 2 Years - 97%
- 3 Years - 3%

\*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.

# Accounting/Internal Controls and Flash Results





# SEC Comments




Excludes prior SEC-reviewed issuers.

# Timing




Excludes prior SEC-reviewed issuers.

# Corporate Governance




**Controlled Company Exemption\***




**Board Composition**

- Average number of directors
- Average number of independent directors



**Separation of Chair and CEO Roles\*\***





**Multiple Classes of Common Stock**

Excludes FPIs (subject to home jurisdiction governance rules).

\*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

\*\*Excludes three issuers that did not have a Chair at the time of IPO.

# Secondary Component and Directed Share Programs (DSPs)







# Deal Structure: Insiders Purchasing in IPO

**77%**

of Health Care  
IPOs had insiders  
purchasing.



**IPOs with Insiders  
Purchasing**




**Percentage of IPO Purchased  
by Health Care Insiders\***

- 5.0%-9.9% purchased - 3%
- 10.0%-19.9% purchased - 7%
- 20.0% or more purchased - 90%


Excludes purchases through a DSP.  
\*Population consists of IPOs with insiders purchasing.

# Deal Structure: Insiders Purchasing in IPO



## Pricing vs. Range

- Above range
- In range
- Below range




## Aftermarket Performance

- Health Care IPOs with insiders purchasing
- All other IPOs with insiders purchasing


Excludes purchases through a DSP.

# Lock-ups and Carve-outs




## Lock-up Release

- Lead left bookrunner only - 8%
- Multiple bookrunners - 92%




## Carve-out for Acquisitions/ Joint Ventures




## Company Lock-up/ Carve-out by Cap

- 5% carve-out - 82%
- 7% carve-out - 9%
- 10% carve-out - 9%

# Fees and Expenses



\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.






# Technology, Media & Telecommunications

# TMT Market Overview

Technology, Media & Telecommunications  
IPOs


**30%**

of overall market




## Sector Overview

- TMT IPOs - 30%
- All other IPOs - 70%




Region of  
Headquarters






Deal Size\*



Over-Allotment Option Exercised





Market Cap at Pricing



- Small-cap (<\$350mm) - 7%
- Mid-cap (\$350mm-\$1bn) - 11%
- Large-cap (\$1bn+) - 82%

\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Market Performance



# Emerging Growth Companies (EGCs)



## Years of Audited Financial Statements\*

- 2 Years - 65%
- 3 Years - 35%







## Years of Selected Financial Statements\*



- 2 Years - 62%
- 3 Years - 38%

\*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.



# Accounting/Internal Controls and Flash Results



# Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




# SEC Comments




Excludes prior SEC-reviewed issuers.

# Timing




Average Number of Days From First Submission/Filing to Pricing




TMT Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

# Corporate Governance




**Controlled Company Exemption\***




**Board Composition**

- Average number of directors
- Average number of independent directors



**Separation of Chair and CEO Roles\*\***



**Multiple Classes of Common Stock**



Excludes FPIs (subject to home jurisdiction governance rules).

\*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.



\*\*Excludes three issuers that did not have a Chair at the time of IPO.



# Secondary Component and Directed Share Programs (DSPs)




# Insiders Purchasing in IPO




Excludes purchases through a DSP.

# Lock-ups and Carve-outs




## Lock-up Release

- Lead left bookrunner only - 14%
- Multiple bookrunners - 86%




## Carve-out for Acquisitions/ Joint Ventures




## Company Lock-up/ Carve-out by Cap

- 5% carve-out - 57%
- 7% carve-out - 6%
- 10% carve-out - 31%
- Uncapped - 6%

# Fees and Expenses



\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.






# Consumer/ Retail

# Consumer/Retail Market Overview

Consumer/Retail  
IPOs


**12%**

of overall market





## Sector Overview

- Consumer/Retail IPOs - 12%
- All other IPOs - 88%



Region of  
Headquarters






**Market Cap at Pricing**

- Mid-cap (\$350mm-\$1bn) - 27%
- Large-cap (\$1bn+) - 73%


\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Market Performance



## Pricing vs. Range



- Above range
- In range
- Below range



## Aftermarket Performance

- Consumer/Retail IPOs
- All other IPOs

# Emerging Growth Companies (EGCs)



## Years of Audited Financial Statements\*

- 2 Years - 33%
- 3 Years - 67%




## Years of Selected Financial Statements\*


- 2 Years - 17%
- 3 Years - 66%
- 5 Years - 17%

\*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.


# Accounting/Internal Controls and Flash Results




**Going Concern**



**Material Weakness**





**Restated Financials**





**Flash Results**

# Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




# SEC Comments




Excludes prior SEC-reviewed issuers.

# Timing




Average Number of Days From First Submission/Filing to Pricing




Consumer/Retail Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

# Corporate Governance




**Controlled Company Exemption\***




**Board Composition**

- Average number of directors
- Average number of independent directors



**Separation of Chair and CEO Roles\*\***



**Multiple Classes of Common Stock**




Excludes FPIs (subject to home jurisdiction governance rules).

\*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

\*\*Excludes three issuers that did not have a Chair at the time of IPO.



# Secondary Component and Directed Share Programs (DSPs)





**Secondary Component**

**DSPs**

**Aftermarket Performance**


- Consumer/Retail IPOs with DSP
- All other IPOs with DSP

# Deal Structure: Insiders Purchasing in IPO




Excludes purchases through a DSP.

# Lock-ups and Carve-outs



## Lock-up Release

- Lead left bookrunner only - 0%
- Multiple bookrunners - 100%




## Carve-out for Acquisitions/ Joint Ventures




## Company Lock-up/ Carve-out by Cap

- 5% carve-out - 58%
- 7% carve-out - 14%
- 10% carve-out - 14%
- Uncapped - 14%

# Fees and Expenses



\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.





# Financial Services

# Financial Services Market Overview


Financial Services  
IPOs

**6%**  
of overall market




**50%**

of the financial  
services issuers in our  
study were commercial  
savings banks.




## Sector Overview

- Financial Services IPOs - 6%
- All other IPOs - 94%




## Region of Headquarters






Deal Size\*



Over-Allotment Option Exercised




Market Cap at Pricing

- Small-cap (<\$350mm) - 33%
- Mid-cap (\$350mm-\$1bn) - 34%
- Large-cap (\$1bn+) - 33%


\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Market Performance



Pricing vs. Range



- Above range
- In range
- Below range



Aftermarket Performance


- Financial Services IPOs
- All other IPOs

# Emerging Growth Companies (EGCs)



## Years of Audited Financial Statements\*

- 2 Years - 100%



## Years of Selected Financial Statements\*



- 2 Years - 25%
- 3 Years - 75%

\*Excludes one EGC that provided financial statements since inception, which period was shorter than two years. The JOBS Act provides financial disclosure requirements for EGCs, requiring only two years of audited financial statements and two years of selected financial data. Non-EGCs are required to include three years of audited financial statements and five years of selected financial data.



# Accounting/Internal Controls and Flash Results



# Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




# SEC Comments




Excludes prior SEC-reviewed issuers.

# Timing




Average Number of Days From First Submission/Filing to Pricing




Financial Services Five-year Trend - Average Number of Days from First Submission/Filing to Pricing

Excludes prior SEC-reviewed issuers.

# Corporate Governance




**Controlled Company Exemption\***




**Board Composition**

- Average number of directors
- Average number of independent directors



**Separation of Chair and CEO Roles\*\***



**Multiple Classes of Common Stock**



Excludes FPIs (subject to home jurisdiction governance rules).

\*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.




\*\*Excludes three issuers that did not have a Chair at the time of IPO.





# Secondary Component and Directed Share Programs (DSPs)



# Lock-ups and Carve-outs



# Fees and Expenses





\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.



# Industrials


# Industrials Market Overview



Industrials IPOs  
**6%**  
of overall market



### Sector Overview

- Industrials IPOs - 6%
- All other IPOs - 94%






**Market Cap at Pricing**

- Mid-cap (\$350mm-\$1bn) - 33%
- Large-cap (\$1bn+) - 67%


\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Market Performance



## Pricing vs. Range

- Above range
- In range
- Below range





## Aftermarket Performance

- Industrials IPOs
- All other IPOs




# Emerging Growth Companies (EGCs)



## Years of Audited Financial Statements\*

- 2 Years - 75%
- 3 Years - 25%




## Years of Selected Financial Statements


- 2 Years - 50%
- 3 Years - 25%
- 5 Years - 25%

\*Non-EGCs are excluded


# Accounting/Internal Controls and Flash Results




Going Concern



Material Weakness





Restated Financials





Flash Results

# Financial Information: Net Loss and EBITDA and/or Adjusted EBITDA




# SEC Comments




Excludes prior SEC-reviewed issuers.

# Timing




**Average Number of Days From First Submission/Filing to Pricing**




**Industrials Five-year Trend - Average Number of Days from First Submission/Filing to Pricing**

Excludes prior SEC-reviewed issuers.

# Corporate Governance




**Controlled Company Exemption\***




**Board Composition**

- Average number of directors
- Average number of independent directors



**Separation of Chair and CEO Roles\*\***





**Multiple Classes of Common Stock**

Excludes FPIs (subject to home jurisdiction governance rules).



\*A controlled company is a company in which more than 50% of the voting power for election of directors is held by an individual, a group or another company. The listing standards of the NYSE and NASDAQ exempt controlled companies from certain corporate governance requirements.

\*\*Excludes three issuers that did not have a Chair at the time of IPO.

# Secondary Component and Directed Share Programs (DSPs)



# Deal Structure: Insiders Purchasing in IPO



Percentage of IPO Purchased  
by Industrials Insiders

● Less than 5% purchased - 100%

Excludes purchases through a DSP.




# Lock-ups and Carve-outs




## Lock-up Release

- Lead left bookrunner only - 0%
- Multiple bookrunners - 100%




## Carve-out for Acquisitions/ Joint Ventures




## Company Lock-up/ Carve-out by Cap

- 5% carve-out - 100%

# Fees and Expenses





\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.







# Appendix A - Sponsor-Backed IPOs

# Sponsor-Backed Overview: Sector Analysis






# Sponsor-Backed Overview: Deal Size & Market Capitalization




\*Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Deal Execution







# Secondary Sales



## Sponsor-Backed IPOs with a Secondary Component



- Sponsor-Backed IPOs without a secondary component - 27%
- Sponsor-Backed IPOs with a secondary component without management selling - 73%



## Sponsor-Backed IPOs with a Secondary Component and Management Selling


- Sponsor-Backed IPOs without a secondary component - 43%
- Sponsor-Backed IPOs with a secondary component without management selling - 57%

# Time to IPO and SEC Comments




\*Excludes prior SEC-reviewed issuers.

# Non-GAAP Financial Measures





**EBITDA and/or  
Adjusted EBITDA  
Disclosure**



**SEC Comments:  
Non-GAAP  
Financial Measures  
Comments**


Excludes prior SEC-reviewed issuers.

# Corporate Governance




Excludes FPIs (subject to home jurisdiction governance rules).

# Board Structure




IPOs with Classified Boards



Average Number of Directors

- Sponsor-Backed - 8
- Non-Sponsor-Backed - 7






Average Number of Independent Directors

- Sponsor-Backed - 5
- Non-Sponsor-Backed - 6



Excludes FPIs (subject to home jurisdiction governance rules).

# Anti-Takeover



Excludes FPIs (subject to home jurisdiction governance rules).

# Fees and Expenses




\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriter in the form of a discount or commission.






# Appendix B - Foreign Private Issuers

# Market Overview: Foreign Private Issuers



# FPI Headquarters





## FPI Headquarters

- 2018
- 2014-2017

# Sector Analysis

There was a greater percentage of TMT and Consumer/Retail IPOs among FPIs as compared to the overall market.

There was a lower percentage of Health Care IPOs among FPIs as compared to the overall market.



Five-Year FPI Sector Trend Analysis


- 2014-2017
- 2018

# Deal Size



FPIs by Deal Size

- Under \$100mm - 27%
- \$100mm-\$249mm - 41%
- \$250mm-\$499mm - 9%
- \$500mm-\$999mm - 9%
- \$1bn+ - 14%





Five-Year FPI Deal Size Trend Analysis

- 2014-2017
- 2018


Deal size consists of priced amount in base offering and excludes any exercise of over-allotment option.

# Market Capitalization at Pricing




# Deal Execution

The over-allotment option was exercised in a lower percentage of FPI IPOs than in the overall market.




# Pricing and Aftermarket Performance



Pricing vs. Range

- Above range
- In range
- Below range




Aftermarket Performance

- FPI IPOs
- Non-FPI IPOs
- All IPOs





# Time to IPO




\*Excludes prior SEC-reviewed issuers and an additional two issuers in 2014, one in 2015, two in 2016, and nine in 2017 with time from first submission/filing to pricing of greater than 18 months.

# Financial Information: Financial Statements




\*FPIs are not required to include quarterly financial statements.



#### Accounting Method Used

- IFRS - 9%
- U.S. GAAP - 91%




#### Disclosure of EBITDA and/or Adjusted EBITDA

- Disclosed - 41%
- Not disclosed - 59%


FPIs are permitted to include financial statements prepared in accordance with IFRS.

# SEC Comments

FPIs received, on average, more comments from the SEC than non-FPIs.



Average Number of First Round SEC Comments





SEC Comment Subject Matter

● FPI IPO  
● Non-FPI IPO



Excludes three prior SEC-reviewed issuers.

# Secondary Component and Insiders Purchasing



\*Does not include purchases through a DSP.

# Fees and Expenses



\*Underwriting fees are the percentage of the IPO base deal that is paid as compensation to the underwriters in the form of a discount or commission.



